Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOP-IMH
2024-517783-37-00Phase 4Authorised
- Sponsor
- Radboud University Medical Center
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of ticagrelor in myocardial infarction (MI) (2 arms), sponsored by Radboud University Medical Center. Primary endpoints: Composite of major adverse cardiac and cerebral events (MACCE), Infarct size by CMR and 1 more. Planned start Sep 2024; status: authorised.
02
Drugs
ticagrelor
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on 2024-517783-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517783-37-00.